Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is an official multisociety hypertension guideline from the AHA/ACC that synthesizes evidence across populations and provides clinical recommendations for practice.
A narrative review synthesizing international hypertension guidelines and evidence from landmark trials to inform clinical management of hypertension in older adults.
A scoping review of preclinical evidence (37 studies, mostly in vitro and animal models) mapping antihypertensive drugs for melanoma; findings are heterogeneous, context-dependent, and the source explicitly states evidence is insufficient to establish reproducible efficacy or translational validity.
A systematic review of 17 studies reporting 25 models for identifying cognitive impairment in hypertensive patients, finding substantial heterogeneity, high risk of bias in 16 studies, limited external validation (4 studies), and poor reproducibility (only 4 fully reproducible), indicating the field lacks mature, validated tools ready for clinical implementation.
Single-center cross-sectional survey of physician knowledge and practice patterns with no comparator arm or outcome data; identifies practice gaps but cannot establish clinical efficacy or guideline concordance quantitatively.
Single-centre observational study describing hypertension prevalence and treatment adequacy in cancer patients; provides descriptive data but lacks comparator group and causal inference.
Large-scale epidemiological analysis of established disease burden using rigorous GBD methodology, confirming and extending known patterns of CKD prevalence and mortality in older adults, but not introducing novel interventions or practice changes.